- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04218162
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean
March 31, 2021 updated by: IlDong Pharmaceutical Co Ltd
A Randomized, Double-blind, Placebo-controlled Parallel Group Study to Evaluate Efficacy and Safety of Lasmiditan Compared to Placebo in the Acute Treatment of Migraine
A randomized, double-blind, placebo-controlled parallel group study to evaluate efficacy and safety of lasmiditan tablet compared to Placebo in the acute treatment of Migraine
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
294
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- IlDong Pharmaceutical Co Ltd
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Able and willing to give written informed consent.
- Male or female, aged 18 years or above.
- Participants with migraine with or without aura fulfilling the International Headache Society (IHS) diagnostic criteria 1.1 and 1.2.1 (International Headache Classification (ICHD-3).
- History of disabling migraine for at least 1 year.
- Migraine Disability Association (MIDAS) score ≥11.
- Migraine onset before the age of 50 years.
- History of 3 - 8 migraine attacks per month (< 15 headache days per month).
- Females of child-bearing potential must be using or willing to use a highly effective form of contraception (e.g. combined oral contraceptive, intrauterine device (IUD), abstinence or vasectomized partner).
- Able and willing to complete an electronic diary to record details of the migraine attack treated with study drug.
Exclusion Criteria:
- Any medical condition or clinical laboratory test which in the judgment of the Investigator makes the participant unsuitable for the study.
- Pregnant or breast-feeding women.
- Known hypersensitivity to lasmiditan or to any excipient of lasmiditan oral tablets, or any sensitivity to lasmiditan.
- History or evidence of hemorrhagic stroke, epilepsy or any other condition placing the participant at increased risk of seizures.
- History of recurrent dizziness and/or vertigo including benign paroxysmal positional vertigo (BPPV), Meniere's disease, vestibular migraine, and other vestibular disorders.
- History of diabetes mellitus with complications (diabetic retinopathy, nephropathy or neuropathy).
- History within the previous three years or current evidence of abuse of any drug, prescription or illicit, or alcohol.
- History of orthostatic hypotension with syncope.
- Significant renal or hepatic impairment.
- Participant is at imminent risk of suicide (positive response to question 4 or 5) on the Columbia-Suicide Severity Rating Scale (C-SSRS) or had a suicide attempt within six months prior to screening.
- Participation in any clinical trial of an experimental drug or device in the previous 30 days.
- Known Hepatitis B or C or human immunodeficiency virus(HIV) infection. History, within past 12 months, of chronic migraine or other forms of primary or secondary chronic headache disorder (e.g. hemicranias continua, medication overuse headache) where headache frequency is ≥15 headache days per month.
- Use of more than 3 doses per month of either opiates or barbiturates.
- Initiation of or a change in concomitant medication to reduce the frequency of migraine episodes within three (3) months prior to Screening/Visit 1.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo
|
Experimental: Lasmiditan 50mg
|
Lasmiditan 50mg
|
Experimental: Lasmiditan 100mg
|
Lasmiditan 100mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Headache Pain Free at 2 Hours Post Dose
Time Frame: 2 hours post dose
|
The percentage of participants defined as mild, moderate, or severe headache pain becoming none.
|
2 hours post dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free
Time Frame: 2 hours post dose
|
The percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing being absent.
|
2 hours post dose
|
Percentage of Participants With Headache Relief
Time Frame: 2 hours post dose
|
The percentage of participants with headache pain moderate or severe which became mild or none or with headache pain mild which became none.
|
2 hours post dose
|
Percentage of Participants Use of Rescue Medication
Time Frame: From 2 Hours Post Dose Up to 24 Hours
|
The percentage of participants who used rescue medication.
|
From 2 Hours Post Dose Up to 24 Hours
|
Number of Participants With Headache Recurrence
Time Frame: 2 Hours Post Dose Up to 48 Hours
|
The number of participants with headache recurrence
|
2 Hours Post Dose Up to 48 Hours
|
Number of Participants With Treatment Emergent Adverse Events
Time Frame: From Baseline Up to End of Study
|
Safety and tolerability was assessed by the number of participants with at least 1 treatment adverse emergent event.
|
From Baseline Up to End of Study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 24, 2020
Primary Completion (Actual)
October 30, 2020
Study Completion (Actual)
October 30, 2020
Study Registration Dates
First Submitted
January 2, 2020
First Submitted That Met QC Criteria
January 2, 2020
First Posted (Actual)
January 6, 2020
Study Record Updates
Last Update Posted (Actual)
April 1, 2021
Last Update Submitted That Met QC Criteria
March 31, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ID-LAS-301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Migraine
-
Behar, Caren, M.D.UnknownMigraine | Migraine Disorders | Migraine Headache | Acute MigraineUnited States
-
PfizerBioshin (Shanghai) Consulting Services Co., LtdCompleted
-
PfizerCompletedAcute MigraineUnited States
-
Neurolief Ltd.CompletedAcute MigraineUnited States, Israel
-
Chordate MedicalTerminated
-
Chordate MedicalTerminated
-
Organon and CoCompleted
-
Organon and CoCompleted
-
Lateral Pharma Pty LtdCompletedAcute MigraineAustralia
-
Eli Lilly and CompanyCoLucid PharmaceuticalsCompletedAcute MigraineUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States